The US Deprescribing Research Network — What it is and what it can do for you

MICHAEL STEINMAN, MD
CYNTHIA BOYD, MD MPH



Disclosures

- •Honoraria from American Geriatrics Society (Beers Criteria of Potentially Inappropriate Medications)
- Co-author of chapter in UptoDate on Multimorbidity
- Co-author of chapter in UptoDate on Deprescribing (coming soon)


- •Thank you!
 - NIA R24 AG064025-1
 - Scientific Advisory Board
 - Malena Spar, Jonathan Norton, Anael Rizzo







Why a network?






Why a network?





Why a network?





Our goals




US Deprescribing Research Network

- Develop a national community for mutual learning and collaborations
- Provide resources and supports
- Develop infrastructure
- Engage stakeholders
- Disseminate



What is the network?













Five pillars

- Investigator development
- Funding for pilot studies and grant-planning activities
- Stakeholder engagement
- Data and resources
- Working Groups



Investigator Development





- Develop interdisciplinary community of investigators interested in deprescribing
 → collaborations, education, career development
- Annual meeting immediately before AGS (May 6)
 - Open to all (!)
 - Junior investigator intensive
 - Travel scholarships
- Webinars
- Virtual works in progress conferences
- Collaboration grants

Annual Network Meeting

First US Deprescribing Research Network Annual Meeting

May 6, 2020

(Immediately Prior to the American Geriatrics Society Annual Meeting) Hyatt Regency Long Beach, Long Beach, CA

Click here to register

Junior Investigator Intensive and Travel Scholarships »



Annual Meeting of USDeN – First is May 6th, 2020, Long Beach, CA

KEYNOTE: CARA TANNENBAUM MD, MSC

CO-FOUNDER AND CO-DIRECTOR OF THE CANADIAN DEPRESCRIBING NETWORK



JAMA | Original Investigation

Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults The D-PRESCRIBE Randomized Clinical Trial

Philippe Martin, PhD; Robyn Tamblyn, PhD; Andrea Benedetti, PhD; Sara Ahmed, PhD; Cara Tannenbaum, MD, MSc

AND MORE....!

- Share research
- Access resources of USDeN
- Stakeholder engagement
- Networking
- Junior Investigator Supports



Annual Meeting of USDeN – Looking ahead to future years











Pilot Awards





- Support early-stage research in deprescribing that has high potential to develop into future large projects
- •Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.
- •\$60K total (directs + indirects)
- Non-US are eligible
- Engage stakeholders

US Deprescribing Research Network

Advancing Research to Optimize Medication Use Among Older Adults Investigator Initiated Proposal Guidelines (USDeN IIP 2020)

The U.S. Deprescribing Research Network is a collaborative research network with the overall goal to support development of investigations studying deprescribing for older adults and to catalyze an expect of high-quality, clinically impactful research in this area. The challenges of excessive medication resident harms, and values-driven decision-making are expected pressing for older adults, particularly those with multiple chronic conditions. Solutions to these challenges require attention to greater propriets, encluding but not infented to plicinate complexity and materialistics across smillips provider and tables of care. Infented to plicinate of proteins, and the particular state of the place of the control of the place of the proteins of the place of the proteins of the place of the proteins of the place of the place of the proteins of the place of the proteins of the place of the proteins of the place of the place of the place of the place of the proteins of the place of the proteins of the place of the proteins of the place of the plac

- 1) Background: Deprescribing is an essential component of safe and effective health care for obter adults. Even with the most intensive effort, it is difficult to prevent older dualit from being stand on medications that may cause more harm than benefit, in adultion, medications that were once helpful for older adults may no longer be advisable to continue, either because the person has developed adverse effects, or because their clinical conditions, overall health, and/or goals of care may have changed since the medication was first prescribed.
- 2) Research Objectives: This funding opportunity is for studies designed to expand the quality, quantity, and translational impact of deprescribing research trapeting older adults. Funding will be provided primarily, but not exclusively by junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, large-scale studies.
- Population of interest: The study must focus on deprescribing efforts impacting older adults and may include an emphasis on patients with multiple chronic conditions, including those with special vulnerabilities, such as dementia.
- 4) Research Methodology: Research is needed in a broad range of areas which include, but are not limited to, delineating the clinical outcomes of deprescribing, identifying behavioral and communication techniques that can constructively engage patients on this topic, determining the effectiveness of deprescribing interventions, and addressing the needs of underserved groups. Different study designs are needed to answer these questions – from pilor research that may lead to future clinical trials, to observational studies, to in deep deputilation.
- 5) Funds available: Maximum period of performance is one year. The articipated total award (directs in indirects) for this grant opportunity is a maximum of 500,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. The combined budgeted total costs will not exceed 500,000 or use an indirect cost rate exceeding each organization's negotiated rate. The possibility of funding exceeding 500,000 or period greater than one year may be considered with special permission; initials

RFA Investigator Initiated Proposal - November 2015

Grant Planning Awards





- Support early-stage research in deprescribing that has high potential to develop into future large projects
- Funding will be provided to support initial development activities that will lead to a multi-site clinical trial or larger-scale research project.
- •\$60K total (directs + indirects)
- Non-US are eligible
- Engage stakeholders
- Expect to fund 4 awards per year total(pilot and grant planning)
- Attend our webinar next month



Advancing Research to Optimize Medication Use Among Older Adults Investigator Initiated Proposal Guidelines (USDeN IIP 2020)

The U.S. Deprescribing Research Network is a collaborative research network with the overall goal to support development of investigations studying deprescribing for older adults, and to catalyze a range of high-quality, clinically impactful research in this area. The challenges of excessive medication use, medication-related harms, and values-driven decision-relating are especially pressing for older adults, particularly those with multiple chronic conditions. Solutions to these challenges require attention to periately presides, including but not intelled to plicinal complexity and multimortability, transitions across multiple provides and sites of care, soler adults values and priorities, and its entiting below across multiple provides and sites of care, soler adults values and priorities, and its entiting below and transitional impact of deprescribing research. Policy grants up to \$50,000 in total costs (direct plus indirect funds) for an one-year period will be awarded to applicants seeking to further research efforts in this field so detailed in the following sections.

- 1) Background: Deprescribing is an essential component of safe and effective health care for older adults. Even with the most intensive efforts, its official to prevent older daults from being stated on medications that may cause more harm than benefit. In addition, medications that were one height for older adults may no longer be advisable to confinue, either because the preson has developed advertee effects, or because their clinical conditions, overall health, and/or goals of care may have changed since the redication was first prescribed.
- 2) Research Objectives: This funding opportunity is for studies designed to expand the quality, quantity, and translational impact of deprescribing research largeling deler adults. Funding will be provided primarily, but not exclusively, to justion investigations whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.
- Population of interest: The study must focus on deprescribing efforts impacting older adults and may include an emphasis on patients with multiple chronic conditions, including those with special vulnerabilities, such as dementia.
- 4) Research Methodology: Research is needed in a broad range of areas which include, but are not limited to, cleimating the circuit autonome of deprescribing, identifying behavioral and communication techniques that can constructively engage patients on this topic, determining the effectiveness of deprescribing interventions, and addressing the needed or underserved groups. Different study designs are needed to answer these questions – from pilor research that may lead to fluture circuita trisis, to observational studies, to in-depth qualitative evaluation.
- 5) Funds available: Maximum period of performance is one year. The articipated total award (directs in violents) for this grant opportunity is a maximum of 560,000. If indirect cost areas have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. The combined budgeted total costs will not exceed 500,000 or use an indirect cost rate exceeding each organization's negotiated rate. The possibility of funding exceeding \$60,000 or specific greater than one year may be considered with special permission' initials.

RFA Investigator Initiated Proposal - November 2011

Pilot and Grant Planning Awards

Decisions about anticoagulation in patients with atrial fibrillation and dementia (Greg Ouellet, Yale)

Older adults' attitudes and preferences about how deprescribing recommendations are discussed (Ariel Green and Nancy Schoenborn, Johns Hopkins)

Intensification and deintensification of glucose-lowering therapies among older adults with diabetes mellitus and MCCs (Jen Kuntz, Kaiser Permanente Northwest)











Stakeholder Engagement







- •Engage stakeholder and community partners to maximize relevance and impact of research on deprescribing
 - Patients, caregivers, health systems leaders

- •Intercalate stakeholders throughout activities of the network pilot studies, annual meeting, webinars, dissemination
- Stakeholder council
- Messaging



Stakeholder Engagement Council: Overview

- Council is comprised of 12-14 members who will represent patient, family, and various organizational and policy perspectives.
- Council members will serve staggered 2-3 year terms over the 5-year study period.

Stakeholder Engagement Council Members		
Name	Organization (if applicable)	Type of stakeholder
Carol Glover		Patients/Caregivers
Katie Maslow		Patients/Caregivers
Suzanne Mintz		Patients/Caregivers
Del Price	PATIENTS network - University of Maryland	Patients/Caregivers
Laura Trejo	LA Department of Aging/Area Agency on Aging	Patients/Caregivers
Frank Federico	Institute for Healthcare Improvement	Health systems and improvement organizations
Vinit Nair	Humana	Health systems and improvement organizations
George Hennawi	MedStar Good Samaritan Hospital	Health systems and improvement organizations
Amy Berman	Hartford Foundation	Policy/advocacy
Shannon Brownlee	Lown Institute	Policy/advocacy
Chad Worz	American Society of Consultant Pharmacists	Professional organization
Nancy Lundenbjerg	American Geriatrics Society	Professional organization
Andrew Auerbach	Society of Hospital Medicine	Professional organization



Data and Resources





- •Develop and share resources and provide supports that will advance research on deprescribing
- •Spearhead initiatives to develop new science and consensus projects around measurement and data
- •Compendia and repositories database of completed and ongoing studies; compendium of measures; repository of DSMB & IRB materials
- Data development, harmonization, management
- Consultation services



Working Groups









Create high-value resources to enhance deprescribing research

- Systematic review and meta-analysis of high-value targets for deprescribing
- Review of measures used in deprescribing research
- Data harmonization collaborative
- •Synthesize knowledge about deprescribing communication, develop "best practices" communication template



Ecosystem, aka Alphabet Soup



US Deprescribing Research Network (USDeN)



Deprescribing.org (Bruyere)



Canadian Deprescribing Network (CaDeN)



Australian Deprescribing Network (ADeN)

English Deprescribing Network (EDeN)

Northern European Deprescribing Network (NERD)

AGING (multimorbidity) Network

Palliative Care Research Cooperative (PCRC)

Network for Investigation of Delirium:

Unifying Scientists (NIDUS)

IMPACT Collaboratory



How can I get involved?





Build research portfolio

 Develop ideas, get inspiration, community

Mentoring

Junior investigator

Grant support



Junior investigator

- Build research portfolio
- Develop ideas, get inspiration, community
- Mentoring
- Grant support

Webinars

Virtual WIPs

Annual meeting

Junior investigator intensive

Learn how to involve stakeholders

Compendia

Consultations

Pilot award





- Expand into new area
- Support mentees
- Learn about national landscape

Not-so-junior investigator



Not-so-junior investigator

- Expand into new area
- Support mentees
- Learn about national landscape

Webinars

Annual meeting - network

Grant planning award

Compendia

Committees





- Want to contribute
- Want to learn

Patient or caregiver





•What is this all about?

Want to contribute

Want to learn

Patient or caregiver

Webinars

Stakeholder activities

Annual meeting



How can I get involved?

- •Join!
- Follow us on Twitter (@DeprescribeUS)
- Annual meeting
- Participate
- Committees

Contact us: admin@DeprescribingResearch.org

Join the Network





Next webinar

WEBINAR

Network-funded pilot and grant planning awards – information for potential applicants

January 7, 2020 | 2:00 - 3:00 PM Eastern / 11:00 - 12:00 PM Pacific

MORE INFORMATION AND REGISTRATION »



DeprescribingResearch.org

